April 04, 2026 —
A new systematic review and meta-analysis published online in the American Journal of Ophthalmology evaluated eight clinical trials involving 203 treated patients and found that gene therapy for neovascular age-related macular degeneration (nAMD) may reduce treatment burden, but has not yet shown consistent improvement in visual acuity. The analysis focused mainly on adeno-associated virus (AAV)-based anti-VEGF strategies designed to provide sustained intraocular expression after a single or infrequent administration.
The study reflects growing interest in gene therapy as a potential alternative or adjunct to conventional anti-VEGF intravitreal injections, which are effective but require frequent long-term dosing. Across pooled data, gene therapy was associated with a significant reduction in central subfield thickness, suggesting a favorable anatomical response. However, this structural improvement did not translate into a statistically significant gain in best-corrected visual acuity, highlighting an ongoing gap between anatomical control and functional visual benefit.
Importantly, the review reported that about 44% of treated eyes still required supplemental anti-VEGF injections. This suggests that current gene therapy approaches are not yet positioned to replace standard-of-care anti-VEGF treatment, but may help reduce injection frequency and ease the burden on patients and retina clinics.
Safety findings were described as generally low to moderate risk across the included studies. Inflammation was reported in roughly 20% of cases and retinal hemorrhage in about 12%, while serious adverse events ranged from 21% to 38%. The authors also noted mortality in the pooled dataset, but cautioned that the underlying studies were small, early phase, and clinically heterogeneous, which limits broad interpretation of these outcomes.
Overall, the review suggests that gene therapy for nAMD is showing encouraging anatomical and durability signals, but the current evidence does not yet support it as a standalone replacement for anti-VEGF injections. Ongoing later-stage studies will be important in determining whether these platforms can deliver sustained visual outcomes and define a clearer role in routine retinal care. For now, gene therapy appears best positioned as a treatment-burden–reducing strategy rather than a full substitute for standard anti-VEGF therapy.
